pharmaphorum

AUGUST 16, 2022

Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to $3.5 billion, consummating a relationship that first started in 2018 and spanned a range of mRNA-based vaccines for infectious diseases. billion, including $150 million upfront.

RNA 92

RNA Vaccination Vaccine Clinical Trials 92

Pharmaceutical Technology

AUGUST 1, 2022

Moderna has entered a new supply contract with the US Government to deliver 66 million doses of its Covid-19 vaccine booster candidate, mRNA-1273.222. The contract comprises a $1.74bn award to produce and supply these vaccine doses and options to further procure up to 234 million additional doses of the company’s booster candidates.

Vaccination 289

Vaccination Vaccine Gene Therapy RNA 289

Bio Pharma Dive

MARCH 18, 2021

A treatment that sprays synthetic messenger RNA into the lungs failed to help cystic fibrosis patients, a blow to efforts to use the technology for more than vaccines.

RNA 311

RNA Vaccination Vaccine Drugs 311

Drug Discovery World

APRIL 11, 2023

US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. Artificial Intelligence (AI) has been enthusiastically adopted by the drug discovery sector as a tool for shortening drug discovery cycle times and increasing success rates.

RNA 52

RNA Medicine Engineer Drugs 52

Drug Discovery World

JUNE 7, 2023

Under the grant, Evotec aims to discover and develop RNA-targeting small molecules as potential first-in-class therapeutics against Henipaviruses. Currently there are no approved drugs or vaccines for neither Hendra nor Nipah virus infections available, underlining an urgent need for accelerated research and development.

RNA 52

RNA Vaccination Vaccine Antibody 52

pharmaphorum

MAY 11, 2021

Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. The post Moderna’s founder launches Laronde, promising new ‘Endless RNA’ drug class appeared first on.

RNA 98

RNA Drugs Protein Immune Response 98

pharmaphorum

OCTOBER 18, 2021

SMi Group’s 13th Annual Conference: RNA Therapeutics 2022. Bolstering the latest advances and opportunities in RNA-based medicine. BENEFITS OF ATTENDING: •Explore how mRNA vaccines have led the way in the response against COVID-19 and key takeaways for the industry. Head of RNA Biology. 9th – 10th February 2022.

RNA 52

RNA Drug Delivery Scientist Clinical Development 52

Drug Discovery World

OCTOBER 2, 2023

This eBook sponsored by DNA Script explores the advances and breakthroughs taking place within vaccines and virology.

Vaccination 52

Vaccination Vaccine RNA DNA 52

Drug Discovery World

FEBRUARY 27, 2023

DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI models. DS: How is Atomic AI “unlocking the next generation of RNA drug discovery”? What is unique about your engine?

RNA 52

RNA Engineer Life Science Drugs 52

Drug Discovery World

FEBRUARY 19, 2024

Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000 , participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg).

Vaccination 52

Vaccination Vaccine Immune Response RNA 52

Drug Discovery World

MAY 13, 2024

Reece Armstrong speaks to Melanie Adams-Cioaba , Senior Director and General Manager of pharma (cryo-EM), Thermo Fisher Scientific about advances in vaccine design. Using structural biology as central to vaccine design and development, and to drug discovery more generally, is what we mean by “rational design.”

Vaccination 59

Vaccination Vaccine Protein Antibody 59

STAT News

JANUARY 19, 2023

Where do new drugs come from? And do normal people care about messenger RNA? Journalist Nathan Vardi joins us to talk about his new book delving into the race to develop the lifesaving cancer drug now called Imbruvica, involving a Scientologist CEO and secretive investor seeking redemption after the worst trade of his life.

Vaccination 115

Vaccination Vaccine Life Science RNA 115

Drug Discovery World

AUGUST 16, 2023

Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines.

RNA 52

RNA Genome Genomics DNA 52

Drug Discovery World

JANUARY 10, 2023

CircRNAs represent an emerging, powerful mechanism for delivering therapeutics and vaccines due to their protein-coding potential and improved stability in comparison to their linear mRNA counterparts. . The post Alliance to develop circular RNA-based therapeutics appeared first on Drug Discovery World (DDW).

RNA 52

RNA Development Gene Therapy Protein 52

Drug Discovery World

MAY 17, 2024

From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent potential breakthroughs in their respective fields. News round-up for 13-16 May by DDW Senior Digital Content Editor Diana Spencer.

Gene Therapy 52

Gene Therapy Gene Drugs In-Vivo 52

Pharmaceutical Technology

JANUARY 30, 2023

According to GlobalData’s Drugs database, there were 22 prophylactic vaccines in development for COVID-19 with sales forecasts available in H2 2022. Of these 22 vaccines, mRNA-derived vaccines dominate, with Comirnaty and Moderna’s Spikvax accounting for 88% of 2022 sales, with 58% and 30%, respectively.

Vaccination 130

Vaccination Vaccine Sales RNA 130

STAT News

JANUARY 25, 2023

From Covid-19 vaccines to therapies against a range of deadly diseases, every RNA molecule has a complex 3D shape that controls its function. A new Bay Area biotech is harnessing artificial intelligence to better understand and predict these structures in hopes of developing new therapeutics. who just turned 30.

RNA 52

RNA Vaccination Vaccine Development 52

STAT News

NOVEMBER 18, 2022

This story has been adapted from the STAT Report “The future of messenger RNA: Covid-19 vaccines are just the beginning.” ” R emember that messenger-RNA-based Covid-19 vaccine you got? Just a few days later, the teeny molecular messengers contained in the shot were already gone.

RNA 105

RNA Containment Vaccination Vaccine 105

Pharmaceutical Technology

AUGUST 24, 2022

Mode rna has submitted an application to the US Food and Drug Administration (FDA) to obtain emergency use authorization (EUA) for mRNA-1273.222, its BA.4/BA.5 5 Omicron-targeting bivalent booster vaccine for Covid-19. The submission is made for a 50µg booster dose of the vaccine for usage in adults aged 18 years and above.

Vaccination 130

Vaccination Vaccine Gene Therapy Antibody 130

pharmaphorum

SEPTEMBER 23, 2021

AstraZeneca has joined the ranks of big pharma companies bolting on RNA-based technology platforms in the wake of the stellar success of mRNA vaccines for COVID-19. The company sees its deal with VaxEquity as going well beyond COVID-19, extending into other vaccines as well as therapeutic drugs.

RNA 52

RNA Immune Response Vaccination Vaccine 52

pharmaphorum

APRIL 30, 2021

With RNA-based technology hitting the headlines in recent months due to its use in Covid vaccines, he also discusses the version of it that Galapagos uses and how it can produce compounds that might alter the course of a disease. The post Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast appeared first on.

RNA 52

RNA Vaccination Vaccine Drugs 52

pharmaphorum

MARCH 16, 2021

European regulators questioned the integrity of early batches of Pfizer/BioNTech’s mRNA vaccine, although the matter was resolved before approval, according to information leaked online following a cyberattack. As it conducted its analysis of the vaccine in December, the European Medicines Agency’s systems were targeted by unknown hackers.

Regulation 133

Regulation Vaccination Vaccine RNA 133

Scienmag

SEPTEMBER 8, 2021

In December 2020, two novel messenger RNA (mRNA) vaccines for SARS-CoV-2 received emergency use authorization from the U.S. Food and Drug Administration; however, the early trials excluded lactating women, leading to questions about their safety in this specific population.

Vaccination 52

Vaccination Vaccine RNA Trials 52

Pharmaceutical Technology

JUNE 6, 2023

The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

RNA 100

RNA Protein Antibody Vaccination 100

Drug Discovery World

JANUARY 12, 2024

This week has seen a number of significant discoveries by researchers in academic institutions, in some cases in partnership with industry, emphasising the important role universities play in early-stage drug discovery. The post This week in drug discovery (8-12 January) appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs Immune Response Allergies Bacteria 52

Drug Discovery World

JUNE 14, 2023

An FDA approval for Pfizer’s Abrysvo respiratory syncytial virus (RSV) vaccine is likely to threaten GSK’s current hold on the market, according to GlobalData. ” Jaser added: “ Abrysvo will likely be the first approved RSV vaccine to protect infants worldwide, potentially leading to a higher market share than its competitors.

Vaccination 52

Vaccination Vaccine FDA Approval RNA 52

pharmaphorum

OCTOBER 2, 2020

Roche’s Genentech unit has paid $200 million to develop an individualised cancer vaccine with Norwegian biotech Vaccibody, which focuses on targets known as neoantigens that spring up as tumours grow and mutate. Frame Therapeutics has also begun work on neoantigen-based cancer vaccines based on RNA technology.

Vaccination 59

Vaccination Vaccine Immune Response Drugs 59

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Scienmag

SEPTEMBER 30, 2020

Scientists are fighting back with multiple strategies, including vaccines, repurposed drugs developed for other diseases and brand-new therapies. Now, researchers reporting in ACS Central Science have identified small molecules that target a structure within the RNA genome […].

RNA 40

RNA Genome Genomics Branding 40

pharmaphorum

DECEMBER 24, 2020

The UK’s COVID-19 vaccination programme could get a speed boost, with the country’s drugs regulator expected to make a decision on a shot from Oxford University/AstraZeneca in the next few days. Just how this will be viewed by regulators is unclear, as are the plans to distribute the vaccine.

Vaccination 126

Vaccination Vaccine Regulation Life Science 126

Drug Discovery World

SEPTEMBER 15, 2023

Spanning artificial intelligence, theranostics, radiopharmaceuticals, quantum simulation and small regulatory RNA, the top stories this week all cover cutting-edge technologies and techniques making a huge impact on modern drug discovery and development.

Drugs 52

Drugs RNA Pharma Companies Vaccination 52

Delveinsight

AUGUST 26, 2021

Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. This system is designed to deliver RNA editing technology or other payloads directly to particular body areas, such as the nervous system or muscle. Datavant inks real-world data partnership with Real Chemistry.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

Drug Discovery World

MARCH 14, 2023

The success of messenger RNA or mRNA vaccines in the fight against the global SARS-CoV-2 crisis brings a new era of vaccine development. In vitro transcription, or IVT, is a complex reaction, requiring key components like an RNA polymerase, nucleotides, and a DNA template to make each mRNA.

Production 52

Production RNA In-Vitro DNA 52

STAT News

MARCH 6, 2023

Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine. Another three received them but later died.

Vaccination 98

Vaccination Vaccine Drugs Clinical Trials 98

VirTrial

OCTOBER 25, 2023

Vaccine studies can be large, multinational endeavors with sensitive timeframes, extended participation follow-up periods, multiphase designs, and critical data management needs. In recent years, Signant has been a part of more than 95 vaccine studies involving 140,000+ patients in more than 30 countries.

Vaccination 52

Vaccination Vaccine Development Clinical Trials 52

Drug Discovery World

APRIL 16, 2023

Personalised mRNA-based cancer vaccine mRNA-4157/V940, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) improved recurrence-free survival (RFS) compared with pembrolizumab alone in patients with high-risk melanoma. According to the results of the primary trial analysis, after 18 months, the RFS was 78.6%

Vaccination 52

Vaccination Vaccine Immune Response Gene Expression 52

pharmaphorum

NOVEMBER 2, 2022

Australia’s CSL is the latest vaccines company to buy into the mRNA category, tapping US biotech Arcturus Therapeutics for a wide-ranging alliance targeting COVID-19, influenza and other respiratory pathogens, including those that may cause future pandemics. For example, Sanofi paid $3.2

Vaccination 52

Vaccination Vaccine Immune Response Gene Therapy 52